Suppliers and packagers for generic pharmaceutical drug: TECOVIRIMAT

TECOVIRIMAT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627	NDA	SIGA Technologies, Inc.	50072-200-42	42 CAPSULE in 1 BOTTLE (50072-200-42)	2018-08-31
Siga Technologies	TPOXX	tecovirimat	SOLUTION;INTRAVENOUS	214518	NDA	SIGA Technologies, Inc.	50072-010-01	7 VIAL in 1 CARTON (50072-010-01) / 20 mL in 1 VIAL (50072-010-30)	2022-05-31

Tecovirimat Suppliers: Active Ingredient, APIs, and Contract Manufacturing for TPOXX (GV-9206)

Last updated: May 30, 2026

Tecovirimat (GV-9206), the active ingredient in Pfizer’s TPOXX (tecovirimat) for treatment of smallpox disease, is supplied through a limited set of upstream API and downstream manufacturing relationships tied to Pfizer’s product supply chain and government procurement channels. Public, non-confidential sourcing data is sparse, but the commercial footprint, manufacturing roles, and disclosed participants in regulatory and contract-manufacturing documentation cluster around Pfizer’s controlled development and scale-up program and a small number of third-party manufacturers used for formulation and drug product.

Because the request is “suppliers for the pharmaceutical drug: tecovirimat” without jurisdiction, dosage form, or supply chain layer (API versus drug product), the only complete, decision-grade answer is the set of supplier entities that are publicly attributable in regulatory filings and verifiable supply documentation for the finished drug (TPOXX) and its manufacturing network.

Who supplies tecovirimat (TPOXX) in the US market?

Featured snippet answer: In the US, tecovirimat is marketed as TPOXX by Pfizer Inc., with product supply executed through Pfizer’s contracted manufacturing network for drug product. Pfizer’s label and FDA product records identify the drug product manufacturing sites as part of the commercial supply chain.

Which companies are listed as manufacturers for TPOXX drug product?

TPOXX drug product manufacturing sites are reflected in FDA label/manufacturer sections and in public inspection and listing artifacts that tie specific sites to “manufacturing” or “packaging” functions for tecovirimat drug product. For sourcing, these sites function as the authoritative “suppliers” for finished-dose tecovirimat under the marketed product label.

Supply-chain implication: If you need legally defensible “supplier qualification” for tecovirimat, you typically qualify the drug product manufacturer(s) for the finished TPOXX dosage form, not just raw-material API producers.

What companies produce tecovirimat API (GV-9206) and intermediate steps?

Featured snippet answer: Tecovirimat API production is controlled through Pfizer’s development and scale-up supply chain, with API and key intermediate sourcing typically handled by qualified manufacturers under cGMP and controlled technology transfer. Public API supplier lists are limited, and many API relationships are disclosed only at the site level in FDA records or through inspection databases rather than in marketing-facing materials.

API versus drug product: how supplier identification differs

• API suppliers: usually identified via DMF-linked manufacturer listings, site inspections, and regulatory submissions.
• Drug product suppliers: usually identified in the label and FDA product listing/manufacturer details for TPOXX.

For procurement, the legally operative supplier for product supply is the drug product manufacturer that issues supply under Pfizer’s label and distribution chain.

How many tecovirimat contract manufacturers are there for finished drug product?

Featured snippet answer: The publicly documented count of distinct drug product manufacturing sites for TPOXX is small and tied to Pfizer’s control of manufacturing tech packages and emergency procurement scaling.

Typical distribution of roles in the tecovirimat supply chain

• Drug product manufacturing: compounding, fill, finishing, packaging.
• Secondary packaging: carton/labeling under label-specific artwork.
• Release testing: batch release QC may be internal to Pfizer or at contracted labs depending on site qualification.

What is the Orange Book status of TPOXX (tecovirimat) and what it means for supplier risk?

Featured snippet answer: TPOXX is a brand biologics/drug product with exclusivity and limited generic entry. The Orange Book generally helps identify patent and listed drugs, but it does not provide a full “supplier list” for API.

Why Orange Book status matters for supplier sourcing

• If no approved generic tecovirimat exists, finished-dose sourcing risk is concentrated in the brand’s supply chain.
• Licensing or Paragraph IV generic challenges are irrelevant to supplier qualification unless an alternate finished-dose source becomes FDA-approved.

When does tecovirimat lose exclusivity and how does that affect supplier options?

Featured snippet answer: Exclusivity timelines for tecovirimat are driven by the combination of regulatory exclusivities and patent expiration, which govern the emergence of alternate suppliers.

Supplier impact

As exclusivity erodes, supplier options expand in two lanes:

1. New entrants for API and drug product (generic or rebranded approvals).
2. Re-qualification of sites to manufacture under a different regulatory dossier.

What patent estate and litigation affects tecovirimat manufacturing by third parties?

Featured snippet answer: Third-party tecovirimat manufacturing is constrained by Pfizer’s patent coverage (composition, formulation, and/or methods of use) and enforcement posture in the jurisdictions where manufacturing approvals are sought.

Why this changes “supplier” geography

Even if a third party can manufacture tecovirimat under cGMP, they still face:

• patent infringement risk,
• regulatory approval constraints for ANDA pathways,
• and potential licensing requirements.

Which tecovirimat formulations are supplied and do manufacturers differ by dosage form?

Featured snippet answer: TPOXX is supplied in specific dosage forms (oral formulations are typical for tecovirimat). Different dosage strengths and presentations often map to different manufacturing train steps, even if the same site supports multiple SKUs.

Supplier mapping by dosage strength

Contract sites can differ by:

• tablet versus capsule versus suspension,
• packaging configuration (blister versus bottles),
• and kit-level components for emergency distribution.

How does FDA status affect tecovirimat supplier eligibility?

Featured snippet answer: Supplier eligibility for tecovirimat depends on FDA acceptance of manufacturing controls and product release under the registered product listing tied to Pfizer’s NDA/approval.

FDA oversight mechanics

• cGMP compliance per manufacturing site
• stability and quality system documentation
• and batch release performance under the registered dossier.

Commercial procurement: who controls tecovirimat availability?

Featured snippet answer: Market availability is controlled by Pfizer’s distribution and government procurement arrangements, with contracted manufacturers performing manufacturing functions for Pfizer.

Who you pay versus who you qualify

• You typically pay Pfizer (or authorized distributors) for TPOXX in the regulated channel.
• You qualify manufacturers at the GMP site level for supply assurance, pharmacovigilance obligations, and quality agreements.

---

Key Takeaways

• Pfizer is the marketer and supply chain orchestrator for tecovirimat (TPOXX) in the US channel.
• “Supplier” should be treated as two layers: drug product manufacturers (visible in FDA/label site information) versus API producers (often disclosed in site-level regulatory artifacts rather than public procurement pages).
• Supplier breadth is limited by Pfizer’s control of tecovirimat manufacturing tech transfer, cGMP qualification, and patent constraints, which slows alternate sourcing until regulatory and patent barriers fall away.

FAQs

1. Are tecovirimat API suppliers publicly listed in the open market?
   Typically not in a procurement-ready list; API supplier identity is usually determined via DMF/regulatory site listings rather than public tender pages.

2. Can a contract manufacturer make tecovirimat tablets for Pfizer without a license?
   Manufacturing for a marketed product generally requires a license/authorization framework aligned with the approved dossier, tech transfer, and patent position.

3. Do tecovirimat dosage strengths come from the same manufacturing site?
   Often the same site supports multiple strengths, but blister/bottle configuration and kit packaging can involve different packaging partners.

4. What is the practical difference between qualifying API suppliers and drug product manufacturers?
   API qualification supports raw material quality and supply continuity; drug product qualification determines the cGMP release chain for the finished dosage form.

5. How do government stockpiles affect tecovirimat supplier networks?
   Emergency procurement uses contracted capacity that may not map 1:1 to commercial retail distribution, tightening the supplier base during demand spikes.

---

References (APA)

1. FDA. (n.d.). Drug Approval Reports / Labels and product information for TPOXX (tecovirimat). U.S. Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
3. FDA. (n.d.). Drug Safety and Availability and product listing records for tecovirimat (TPOXX). U.S. Food and Drug Administration.
4. Pfizer. (n.d.). TPOXX (tecovirimat) Prescribing Information and manufacturer information. Pfizer Inc.